|
GB581334A
(en)
|
1943-09-29 |
1946-10-09 |
Francis Henry Swinden Curd |
New pyrimidine compounds
|
|
JPS4921148B1
(enExample)
|
1970-12-28 |
1974-05-30 |
|
|
|
JPS4921149B1
(enExample)
|
1970-12-28 |
1974-05-30 |
|
|
|
DE2341925A1
(de)
|
1973-08-20 |
1975-03-06 |
Thomae Gmbh Dr K |
Neue pyrimidinderivate und verfahren zu ihrer herstellung
|
|
AT340933B
(de)
|
1973-08-20 |
1978-01-10 |
Thomae Gmbh Dr K |
Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
|
|
US4994386A
(en)
|
1987-07-13 |
1991-02-19 |
Pharmacia Diagnostics, Inc. |
Production of HBLV virus in the HSB-2 cell line
|
|
US4929726A
(en)
|
1988-02-09 |
1990-05-29 |
Georgia State University Foundation, Inc. |
Novel diazines and their method of preparation
|
|
EP0330263A1
(en)
|
1988-02-25 |
1989-08-30 |
Merck & Co. Inc. |
Piperazinylalkylpyrimidines as hypoglycemic agents
|
|
GB9012311D0
(en)
|
1990-06-01 |
1990-07-18 |
Wellcome Found |
Pharmacologically active cns compounds
|
|
WO1992000970A1
(en)
|
1990-07-03 |
1992-01-23 |
Mitsui Petrochemical Industries, Limited |
Pyrimidine compound and pharmaceutically acceptable salt thereof
|
|
WO1996032384A1
(en)
|
1995-04-13 |
1996-10-17 |
Taiho Pharmaceutical Co., Ltd. |
Novel 4,6-diarylpyrimidine derivatives and salts thereof
|
|
JP3734907B2
(ja)
|
1996-12-19 |
2006-01-11 |
富士写真フイルム株式会社 |
現像処理方法
|
|
US6251900B1
(en)
|
1997-07-24 |
2001-06-26 |
Zenyaku Kogyo Kabushiki Kaisha |
Heterocyclic compounds and antitumor agent containing the same as active ingredient
|
|
JPH11158073A
(ja)
|
1997-09-26 |
1999-06-15 |
Takeda Chem Ind Ltd |
アデノシンａ３拮抗剤
|
|
US6440965B1
(en)
|
1997-10-15 |
2002-08-27 |
Krenitsky Pharmaceuticals, Inc. |
Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
|
|
US6150362A
(en)
|
1997-12-12 |
2000-11-21 |
Henkin; Jack |
Triazine angiogenesis inhibitors
|
|
ATE236136T1
(de)
|
1998-01-16 |
2003-04-15 |
Hoffmann La Roche |
Benzosulfonderivate
|
|
WO1999065897A1
(en)
|
1998-06-19 |
1999-12-23 |
Chiron Corporation |
Inhibitors of glycogen synthase kinase 3
|
|
US7045519B2
(en)
|
1998-06-19 |
2006-05-16 |
Chiron Corporation |
Inhibitors of glycogen synthase kinase 3
|
|
US6495558B1
(en)
|
1999-01-22 |
2002-12-17 |
Amgen Inc. |
Kinase inhibitors
|
|
AU768201B2
(en)
|
1999-01-22 |
2003-12-04 |
Amgen, Inc. |
Kinase inhibitors
|
|
US6329380B1
(en)
|
1999-06-30 |
2001-12-11 |
Merck & Co., Inc. |
SRC kinase inhibitor compounds
|
|
EP1194152A4
(en)
|
1999-06-30 |
2002-11-06 |
Merck & Co Inc |
Links to SRC kinase inhibition
|
|
JP2003523942A
(ja)
|
1999-06-30 |
2003-08-12 |
メルク エンド カムパニー インコーポレーテッド |
Ｓｒｃキナーゼ阻害剤化合物
|
|
CA2379064A1
(en)
|
1999-07-15 |
2001-01-25 |
Pharmacopeia, Inc. |
Bradykinin b1 receptor antagonists
|
|
JP2001089452A
(ja)
|
1999-09-22 |
2001-04-03 |
Sankyo Co Ltd |
ピリミジン誘導体
|
|
WO2001060816A1
(en)
|
2000-02-17 |
2001-08-23 |
Amgen Inc. |
Kinase inhibitors
|
|
AU2001242629B2
(en)
|
2000-03-29 |
2005-08-11 |
Cyclacel Limited |
2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
|
|
CN1186324C
(zh)
|
2000-04-27 |
2005-01-26 |
山之内制药株式会社 |
稠合杂芳基衍生物
|
|
KR100711042B1
(ko)
|
2000-04-28 |
2007-04-24 |
다나베 세이야꾸 가부시키가이샤 |
환상 화합물
|
|
EP1296977A1
(en)
|
2000-06-23 |
2003-04-02 |
Bristol-Myers Squibb Pharma Company |
Heteroaryl-phenyl substituted factor xa inhibitors
|
|
CN100506801C
(zh)
|
2000-09-06 |
2009-07-01 |
诺华疫苗和诊断公司 |
糖元合成酶激酶3的抑制剂
|
|
WO2002022604A1
(en)
|
2000-09-15 |
2002-03-21 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
SE0004053D0
(sv)
|
2000-11-06 |
2000-11-06 |
Astrazeneca Ab |
N-type calcium channel antagonists for the treatment of pain
|
|
CA2432131C
(en)
|
2000-12-21 |
2008-07-08 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
WO2002062766A2
(en)
|
2001-02-07 |
2002-08-15 |
Millennium Pharmaceuticals, Inc. |
Melanocortin-4 receptor binding compounds and methods of use thereof
|
|
AU2002258400A1
(en)
|
2001-02-16 |
2002-08-28 |
Tularik Inc. |
Methods of using pyrimidine-based antiviral agents
|
|
EP1395561A1
(en)
|
2001-05-25 |
2004-03-10 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Carbamate and oxamide compounds as inhibitors of cytokine production
|
|
CA2450934A1
(en)
|
2001-06-19 |
2002-12-27 |
Marco Dodier |
Pyrimidine inhibitors of phosphodiesterase (pde) 7
|
|
US6603000B2
(en)
|
2001-07-11 |
2003-08-05 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Synthesis for heteroarylamine compounds
|
|
WO2003030909A1
(en)
|
2001-09-25 |
2003-04-17 |
Bayer Pharmaceuticals Corporation |
2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
|
|
WO2004078163A2
(en)
|
2003-02-28 |
2004-09-16 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
|
|
EP1485100B1
(en)
|
2002-03-15 |
2010-05-05 |
Vertex Pharmaceuticals Incorporated |
Azinylaminoazoles as inhibitors of protein kinases
|
|
US20040009981A1
(en)
|
2002-03-15 |
2004-01-15 |
David Bebbington |
Compositions useful as inhibitors of protein kinases
|
|
AU2003220300A1
(en)
|
2002-03-15 |
2003-09-29 |
Binch, Hayley |
Compositions useful as inhibitors of protein kinases
|
|
ATE433973T1
(de)
|
2002-03-15 |
2009-07-15 |
Vertex Pharma |
Azolylaminoazine als inhibitoren von proteinkinasen
|
|
US20040082627A1
(en)
|
2002-06-21 |
2004-04-29 |
Darrow James W. |
Certain aromatic monocycles as kinase modulators
|
|
JP2006510597A
(ja)
|
2002-09-27 |
2006-03-30 |
メルク エンド カムパニー インコーポレーテッド |
置換ピリミジン類
|
|
AU2003288925A1
(en)
|
2002-10-08 |
2004-05-04 |
Massachusetts Institute Of Technology |
Compounds for modulation of cholesterol transport
|
|
US7223870B2
(en)
|
2002-11-01 |
2007-05-29 |
Pfizer Inc. |
Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
|
|
CA2507100C
(en)
|
2002-11-21 |
2012-10-09 |
Chiron Corporation |
2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
|
|
JP2006521357A
(ja)
|
2003-03-24 |
2006-09-21 |
メルク エンド カムパニー インコーポレーテッド |
ナトリウムチャンネル遮断薬としてのビアリール置換６員複素環化合物
|
|
US20050014753A1
(en)
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
|
EP1610774A4
(en)
|
2003-04-09 |
2008-07-16 |
Exelixis Inc |
TIE-2 MODULATORS AND METHODS OF USE
|
|
EP1651619A1
(en)
|
2003-07-15 |
2006-05-03 |
Neurogen Corporation |
Substituted pyrimidin-4-ylamin analogues as vanilloid receptor ligands
|
|
CA2531619A1
(en)
|
2003-07-16 |
2005-01-27 |
Neurogen Corporation |
Biaryl piperazinyl-pyridine analogues
|
|
PE20050952A1
(es)
|
2003-09-24 |
2005-12-19 |
Novartis Ag |
Derivados de isoquinolina como inhibidores de b-raf
|
|
AU2005232745A1
(en)
|
2004-04-13 |
2005-10-27 |
Astellas Pharma Inc. |
Polycyclic pyrimidines as potassium ion channel modulators
|
|
GB0415365D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
GB0415364D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
MY145822A
(en)
|
2004-08-13 |
2012-04-30 |
Neurogen Corp |
Substituted biaryl piperazinyl-pyridine analogues
|
|
EP1827434B1
(en)
*
|
2004-11-30 |
2014-01-15 |
Amgen Inc. |
Quinolines and quinazoline analogs and their use as medicaments for treating cancer
|
|
JP2008523156A
(ja)
|
2004-12-13 |
2008-07-03 |
ニューロジェン・コーポレーション |
置換ビアリール類縁体
|
|
EP1824490A4
(en)
|
2004-12-13 |
2008-06-04 |
Neurogen Corp |
PIPERAZINYL-PYRIDINE ANALOGS
|
|
JP5124285B2
(ja)
|
2004-12-28 |
2013-01-23 |
キネックス ファーマシューティカルズ， エルエルシー |
細胞増殖性障害を処置する組成物および方法
|
|
AU2006206246A1
(en)
|
2005-01-19 |
2006-07-27 |
Neurogen Corporation |
Heteroaryl substituted piperazinyl-pyridine analogues
|
|
EP1877388A2
(en)
|
2005-02-25 |
2008-01-16 |
Kudos Pharmaceuticals Ltd |
Hydrazinomethyl, hydrazonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
|
|
EP1871762A2
(en)
|
2005-04-18 |
2008-01-02 |
Neurogen Corporation |
Subtituted heteroaryl cb1 antagonists
|
|
GB2431156A
(en)
|
2005-10-11 |
2007-04-18 |
Piramed Ltd |
1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
|
|
AU2007204208A1
(en)
|
2006-01-11 |
2007-07-19 |
Astrazeneca Ab |
Morpholino pyrimidine derivatives and their use in therapy
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
EP2012794B1
(en)
*
|
2006-04-13 |
2014-09-17 |
The Trustees of Columbia University in the City of New York |
Compositions and intraluminal devices for inhibiting vascular stenosis
|
|
AR064571A1
(es)
|
2006-12-28 |
2009-04-08 |
Basf Ag |
Pirimidinas sustituidas en posicion 2 por heterociclos nitrogenados, medicamentos y composiciones farmaceuticas que las contienen y usos de las mismas en el tratamiento del cancer.
|
|
EA200901065A1
(ru)
|
2007-02-06 |
2010-02-26 |
Новартис Аг |
Ингибиторы pi 3-киназы и способы их применения
|
|
US7957951B2
(en)
|
2007-03-16 |
2011-06-07 |
Robert Bosch Gmbh |
Address translation system for use in a simulation environment
|
|
AR067478A1
(es)
|
2007-07-09 |
2009-10-14 |
Astrazeneca Ab |
Compuestos derivados de morfolina pirimidina
|
|
WO2009066084A1
(en)
|
2007-11-21 |
2009-05-28 |
F. Hoffmann-La Roche Ag |
2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
|
|
CN105343102A
(zh)
|
2008-03-05 |
2016-02-24 |
诺华股份有限公司 |
嘧啶衍生物在治疗egfr依赖性疾病或对靶向egfr家族成员的物质具有获得性耐药性的疾病中的用途
|
|
CA2925257C
(en)
|
2008-03-26 |
2019-04-30 |
Carlos Garcia-Echeverria |
5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
|
|
WO2009120094A2
(en)
|
2008-03-27 |
2009-10-01 |
Auckland Uniservices Limited |
Substituted pyrimidines and triazines and their use in cancer therapy
|
|
JP5277256B2
(ja)
|
2008-04-09 |
2013-08-28 |
田辺三菱製薬株式会社 |
ｍａｘｉ−Ｋチャネル開口薬としてのピリミジン、ピリジン及びトリアジン誘導体
|
|
GB0815369D0
(en)
|
2008-08-22 |
2008-10-01 |
Summit Corp Plc |
Compounds for treatment of duchenne muscular dystrophy
|
|
AU2009309616B2
(en)
|
2008-10-31 |
2014-02-13 |
Novartis Ag |
Combination of a phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor
|
|
GB2465405A
(en)
|
2008-11-10 |
2010-05-19 |
Univ Basel |
Triazine, pyrimidine and pyridine analogues and their use in therapy
|
|
WO2010068863A2
(en)
|
2008-12-12 |
2010-06-17 |
Cystic Fibrosis Foundation Therapeutics, Inc. |
Pyrimidine compounds and methods of making and using same
|
|
RU2535217C2
(ru)
|
2009-02-06 |
2014-12-10 |
Ниппон Синяку Ко., Лтд. |
Производные аминопиразина и лекарственные средства
|
|
JP5747440B2
(ja)
|
2009-02-06 |
2015-07-15 |
住友化学株式会社 |
ヒドラジド化合物及びその有害生物防除用途
|
|
ES2740424T3
(es)
|
2009-03-13 |
2020-02-05 |
Agios Pharmaceuticals Inc |
Métodos y composiciones para trastornos relacionados con la proliferación celular
|
|
WO2010120994A2
(en)
|
2009-04-17 |
2010-10-21 |
Wyeth Llc |
Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
|
|
SI2432767T1
(sl)
|
2009-05-19 |
2013-10-30 |
Dow Agrosciences Llc |
Spojine in postopki za zatiranje gliv
|
|
US8486939B2
(en)
|
2009-07-07 |
2013-07-16 |
Pathway Therapeutics Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
|
AR077695A1
(es)
|
2009-08-04 |
2011-09-14 |
Schering Corp |
Derivados de pirimidina como inhibidores del factor ixa
|
|
AR077999A1
(es)
|
2009-09-02 |
2011-10-05 |
Vifor Int Ag |
Antagonistas de pirimidin y triazin-hepcidina
|
|
KR20120063515A
(ko)
|
2009-09-09 |
2012-06-15 |
아빌라 테라퓨틱스, 인크. |
Ｐｉ３ 키나제 억제제 및 이들의 용도
|
|
WO2011072174A1
(en)
|
2009-12-09 |
2011-06-16 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
|
|
GB201004200D0
(en)
|
2010-03-15 |
2010-04-28 |
Univ Basel |
Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
|
|
WO2011133920A1
(en)
|
2010-04-23 |
2011-10-27 |
Cytokinetics, Inc. |
Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
|
|
AR081331A1
(es)
|
2010-04-23 |
2012-08-08 |
Cytokinetics Inc |
Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
|
|
AR081626A1
(es)
|
2010-04-23 |
2012-10-10 |
Cytokinetics Inc |
Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
|
|
US20130109643A1
(en)
|
2010-05-10 |
2013-05-02 |
The Johns Hopkins University |
Metabolic inhibitor against tumors having an idh mutation
|
|
US20130184222A1
(en)
|
2010-07-16 |
2013-07-18 |
Agios Pharmaceuticals, Inc |
Therapeutically active compositions and their methods of use
|
|
CA2813333C
(en)
|
2010-10-01 |
2019-01-15 |
Novartis Ag |
Manufacturing process for pyrimidine derivatives
|
|
KR101823615B1
(ko)
|
2010-10-18 |
2018-01-30 |
세레니스 쎄라퓨틱스 홀딩 에스에이 |
콜레스테롤 이동에 유용한 화합물, 조성물 및 방법
|
|
GB201106829D0
(en)
|
2011-04-21 |
2011-06-01 |
Proximagen Ltd |
Heterocyclic compounds
|
|
AU2012214413A1
(en)
|
2011-02-11 |
2013-08-22 |
Dana-Farber Cancer Institute, Inc. |
Method of inhibiting hamartoma tumor cells
|
|
CN102827073A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
|
CA2846272A1
(en)
|
2011-09-01 |
2013-03-07 |
Novartis Ag |
Pi3k inhibitor for use in the treatment of bone cancer or for preventing metastatic dissemination primary cancer cells into the bone
|
|
ES2645968T3
(es)
|
2011-09-27 |
2017-12-11 |
Novartis Ag |
3-(pirimidin-4-il)-oxazolidin-2-onas como inhibidores de IDH mutante
|
|
WO2013052395A1
(en)
|
2011-10-06 |
2013-04-11 |
Merck Sharp & Dohme Corp. |
1,3-substituted azetidine pde10 inhibitors
|
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
|
SG11201406550QA
(en)
*
|
2012-05-16 |
2014-11-27 |
Novartis Ag |
Dosage regimen for a pi-3 kinase inhibitor
|
|
WO2013184621A1
(en)
|
2012-06-06 |
2013-12-12 |
Novartis Ag |
Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
|
|
RU2705095C2
(ru)
|
2012-08-16 |
2019-11-05 |
Новартис Аг |
Комбинация ингибитора pik3 и ингибитора с-мет
|
|
AU2013336807B2
(en)
|
2012-10-23 |
2016-10-27 |
Novartis Ag |
Improved process for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine
|
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
|
AU2014229313B2
(en)
|
2013-03-14 |
2016-07-28 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
|
|
KR20150127197A
(ko)
|
2013-03-14 |
2015-11-16 |
노파르티스 아게 |
돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
|
|
CN103483345B
(zh)
|
2013-09-25 |
2016-07-06 |
中山大学 |
Pi3k激酶抑制剂、包含其的药物组合物及其应用
|
|
CN103694218B
(zh)
|
2013-12-05 |
2016-04-27 |
中山大学 |
嘧啶化合物、pi3k抑制剂、包含pi3k抑制剂的药物组合物及应用
|